14.6 C
New York
Saturday, November 21, 2026

Roundup $7.25 Billion Settlement Approved by Judge

Must read

Rajiv
Rajivhttps://trendsnewsstories.com/
Rajiv writes and edits news and explainers for Trends News Stories, based in New Delhi, India.

A Missouri judge on Friday approved Bayer’s $7.25 billion settlement of lawsuits alleging that its weedkiller Roundup causes cancer, a decision that could end litigation that has weighed on the German company for close to a decade. St. Louis Circuit Judge Timothy Boyer found the settlement “fair, reasonable, and adequate” in a written judgment, calling the total amount “among the largest in the history of mass tort personal-injury class action settlements.” The nationwide class settlement covers people who used Roundup and developed non-Hodgkin lymphoma, a form of cancer, and it also covers people who receive that diagnosis in future years. Bayer said the approval was a decisive step in its plan to contain the Roundup litigation. The order can still be appealed.

What the Roundup settlement pays

People covered by the settlement could receive average payouts of $10,000 to $165,000, depending on how they used the product, how old they were when diagnosed and how severe their illness is. The settlement also includes $600 million for attorneys’ fees. Monsanto, the Bayer unit that makes the weedkiller, will make declining capped annual payments into a special fund for up to 21 years. The payments total as much as $7.25 billion, including money already paid. Bayer bought Monsanto for $63 billion in 2018, and the lawsuits followed Bayer from that deal. The company has settled earlier cases while new claims kept coming. Friday’s ruling gives Bayer a fixed structure for the claims that remain.

Roundup litigation after the Supreme Court ruling

The approval came five months after the U.S. Supreme Court ruled in June in the Durnell case that federal pesticide law preempts failure-to-warn claims brought in state court. The 7-2 decision limited one of the main legal theories behind the Roundup cases, and Boyer cited it in finding that the settlement met the test for adequacy. In October, a Missouri jury sided with Bayer in the first Roundup verdict since that ruling, rejecting claims of design defects, negligence and fraud in a case known as Aretino. Bayer said the class settlement and the Durnell ruling work together to contain the Roundup litigation.

The settlement was filed in St. Louis Circuit Court, home to Bayer’s North America crop science division and the state where many of the lawsuits were brought. It covers two groups. The first includes people who say they were exposed to the weedkiller before February 17, 2026, and have a diagnosis of non-Hodgkin lymphoma now. The second includes people who receive a diagnosis of the disease before the end of a 16-year period after final approval of the agreement. Bayer Chief Executive Bill Anderson said in a statement that the court-approved settlement is “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future” litigation. He used the same phrase in a company release on Friday.

The litigation has run for close to a decade. Bayer has already paid out money on earlier claims, and new claims kept coming as more people came forward. The nationwide class structure is meant to bring that sprawl under one agreement. It covers current claims and claims that have not yet been filed, a point Bayer stressed in its statement on Friday. Whether the agreement holds will depend in part on appeals, which can still be filed against the approval order.

How the Roundup claims program works

The class settlement sets up a long-term claims program that will resolve present and future Roundup injury claims, regardless of the legal theory behind them. The court’s final approval order is subject to appeal, and the judge rejected numerous objections to the proposal before granting approval. Bayer said the approval, combined with the Supreme Court ruling, gives it a way to put a boundary around the litigation. For the people covered, the next step is the claims process, which will sort applications by exposure history and medical records. The company said the program will run for years, with payments spread across the 21-year schedule. The fund will pay claims over time rather than in a single lump sum, and the annual amounts decline over the life of the program.

More articles

Latest article